Buy Kd 9 [BETTER]
The Nike KD 9, Kevin Durant's ninth signature sneakers, was first released in June 2016. The sneaker was fitted with a number of new technologies being debuted by Nike. The KD 9 was the first sneaker Kevin Durant wore when he began playing with the Golden State Warriors. The KD 9 Elite, a more technically advanced version of the original, was released during the NCAA Tournament in March 2017.
buy kd 9
With Air Zoom and phylon combined in the midsole, the KD 9 sneakers provide athletes with bounce and responsiveness. The phylon is lightweight, responsive EVA foam with a low profile on top of the midsole for flexibility and cushioning. The ultra-thin, full-length Air Zoom underneath the phylon provides firm support while improving maneuverability on the court. The synthetic fibers within the compressed plastic of the Air Zoom are designed to improve the court feel for players.
The Flyknit upper is designed to provide flexibility and support. The honeycomb outsole is designed to support the multidirectional movements of quicker athletes indoors or outdoors. The soft, pliable rubber compound of the sole is designed to enhance grip on different types of surfaces. The stretchable neoprene in the extended ankle is designed to enhance players' flexibility and stability.
The Flyknit is designed to help the Nike KD 9 sneakers provide a snugger fit from the midfoot to the toes. The material used is thin, soft, and offers breathability. The Flywire lockdown system helps the KD Elite 9 fit like a glove, using five eyelets to minimize height while supporting the heel and forefoot. The laces are designed to wrap around the ankle for better lockdown, containment, and dynamic support.
The top wires on these high-upper basketball shoes can be tightened to provide your ankles with additional support. Both sneakers are designed on Kevin Durant's foot structure so they rarely fit true to size in length or width. These sneakers favor wearers with narrow feet so athletes, especially those with wider feet, must shop for a half-size larger. See the manufacturer's site for details.
The KD 9 sneaker features tapered Zoom Air running from head to toe, a honeycomb Flyknit upper, and an anatomically articulated flex-groove outsole. The Nike KD Elite features Zoom Air, Dynamic Flywire lacing, a Flyknit upper, phylon midsole, and an extended ankle sleeve made of neoprene. Both versions of the Nike KD 9 feature visible, full-length Zoom Air. These Leo Chang designed sneakers are built to meet Kevin Durant's needs on and off the court.
Chang and Durant worked together to design basketball shoes that could also be worn as fashion sneakers. Nike currently offers these sneakers in over 20 different colorways, including the Xmas KD shoes. The KD 9 Elite is available in up to four different colorways. The Nike Swoosh is positioned on both sides of the sneaker, and the color often coincides with the shade of the colorway.
Step up your game with the latest Nike news, guides and releases on the eBay Sneakers Hub. From classic silhouettes to new Nike Dunk and Nike Air collaborations, you'll find everything you need to know to stay ahead of the game.
COMPLEX participates in various affiliate marketing programs, which means COMPLEX gets paid commissions on purchases made through our links to retailer sites. Our editorial content is not influenced by any commissions we receive.
It didn't take long for Nike to capitalize on Kevin Durant's major decision to leave the OKC Thunder and sign with the Golden State Warriors. Just days after Durant's announcement, the brand has made available his latest shoe, the KD 9, in Warriors colors.
These custom options for the KD 9 are available here, and are limited to Warriors colors like royal and yellow. There's also a multicolor Flyknit treatment that's exclusive to North America.
Every item at KICKS CREW goes through a rigorous authentication process by our expert team. Tracking number are usually provided with 7 business days, varies on arrangement of an order.
The buyer will be entitled to a partial refund once the item(s) are returned successfully. The initial delivery fee is non-refundable, and a restocking fee (15% of the total transaction payment) will be deducted from the transaction amount.
Several attempts have been made to develop a gold standard for diagnostic test in KD. The aim of this study was to describe the clinical course with special interest in cardiac involvement, treatment and follow-up of Polish patients with KD as an experience of a single-center study.
Diagnosis was based on clinical criteria described in American Heart Association (AHA) scientific statement on diagnosis, treatment, and long-term management of KD. Clinical features, laboratory results and treatment were evaluated. Besides medical history and careful physical examination, functional and imaging examinations, such as transthoracic echocardiography, electrocardiogram (ECG), and chest X-ray (CXR) examinations were assessed in each child.
Several laboratory tests were taken into consideration as supportive of the KD diagnosis. According to the AHA guidelines, ALT activity and albumin levels were also taken into consideration in this study. Apart from these guidelines, we also assessed some other parameters that were tested in previous studies of KD to prepare an algorithm for clinical aid of the diagnosis. These included peripheral complete blood count, gamma-glutamyl transferase (GGTP), fibrinogen, d-dimers or ferritin serum levels, as well as the full lipoprotein profile. All those laboratory tests were done by the standard methods.
The study group consisted of 37 patients (24 boys and 13 girls). The median age of the patients was 3 years, (min. 0.4; max. 10 years). The median time of hospitalization equaled 14 days (min. 6; max. 32 days).
Sixteen out of thirty-seven children were admitted to our Department from another hospital with suspicion of pneumonia, and three patients with a diagnosis of pharyngitis. One patient (1/37) was previously treated for Herpes simplex virus (HSV) infection, four patients (4/37) were admitted as unknown infection, and another two children (2/37) were initially treated for sepsis/neuroinfection. Two patients (2/37) had lymphadenopathy and one patient (1/37) had gastrointestinal infection. One child (1/37) had a suspicion of connective tissue disease. Only 7 out of 37 patients were referred to a hospital on suspicion of KD (Table 1).
All the patients had fever present for at least 5 days; in three-fourth of the cases, this symptom was due to KD. Nine out of thirty-seven children were diagnosed as incomplete KD. Other symptoms commonly associated with the typical indicators of KD were hepatomegaly (13/37 patients), arthritis (9/37 patients), hyperesthesia (5/37 patients), and splenomegaly (one patient) (Fig. 1). Only one child was diagnosed with atypical KD; he presented fever and three criteria of KD; however, unusual symptoms such as arthritis, hyperesthesia, hepatomegaly and peritoneal effusion occurred.
Twenty-nine out of thirty-seven patients had oropharyngeal changes such as cracked or erythematous lips or strawberry tongue. In three-fourth of children, lymphadenopathy and conjunctivitis were detected.
The least detected symptom in the study group was pleural or peritoneal effusion, which occurred in four children (4/37; one case of pleural effusion and three cases of peritoneal effusion), respectively.
The applied treatment included an infusion of IVIG at a dose of 2 g/kg, an oral dose of ASA initially in an anti-inflammatory dose, then in an anticoagulant dose. Two patients (2/37) received only ASA therapy due to the mild course of the disease and no changes in the coronary arteries. Four patients (4/37) required a double infusion of IVIG. In seven patients (7/37), systemic steroid therapy was additionally applied, mostly in patients with persistent arthritis and fever. One patient required an intravenous infusion of albumins. Mean day of administration of IVIG in the study group was between 9th and 10th day of the disease. Eleven out of thirty-seven patients received IVIG treatment after the 10th day of the disease. All of these patients presented abnormalities in the echocardiogram: three patients had vulvar regurgitations, five patients had dilatation of coronary arteries, eight patients suffered from pericardial effusion and two patients developed coronary artery aneurysms (some patients presented more than one abnormality).
Each patient had a follow-up 4 weeks after the diagnosis. Thirty-five out of thirty-seven children obtained normalization of CRP level and thirty-one out of thirty-seven children obtained a correct ESR. Ten patients (10/37) still had elevated PLT count at the 4-week follow-up. Eighteen of patients (18/37) required maintenance of anticoagulant therapy in a form of acetylsalicylic acid due to sustained changes in coronary arteries. After 4 weeks, changes in the lipid profile of the children were at the same level as during the acute phase of the disease. One child had elevated fibrinogen level and two children had elevated d-dimer level after 4 weeks.
Recent reports showed steady increase in the prevalence of KD. Viral or bacterial infections, autoimmune factors, and genetic factors have been suggested as a key agents in KD pathogenesis [7, 8]. Our study confirms these observations, at least in regard to prevalence of infections preceding KD diagnosis. Importantly, all our patients had fever lasting 5 or more days. This may reflect activity of proinflammatory cytokines, believed to mediate the underlying coronary artery inflammation.
Among our patients, nearly 1/4 of cases met the criteria of incomplete KD. Thirty-six out of thirty-seven patients presented abnormalities in echocardiogram (Figs. 2, 3). Among 24 patients with dilatations/aneurysms of coronary arteries, six patients (1/4 of the group) presented incomplete KD and five patients (1/5 of the group) received IVIG treatment after the 10th day of disease. This group of patients presented higher ESR level and higher platelet count than a group of patients without changes in the coronary arteries. In addition, 86.6% of this group was male, and the median age of patients was 1.9 years, which is consistent with other reports which state that male gender and younger age are a risk factor for the development of coronary artery abnormalities [9]. There was no statistically significant correlation between coronary artery aneurysms and results of laboratory tests. Mean day of administration of IVIG in the study group was between 9th and 10th day of the disease. Such a delayed time of IVIG administration was caused by an extended period of time after which some patients were admitted to our department from local hospitals. Due to persistent inflammation and confirmation of the diagnosis, we decided to administer IVIG treatment despite the fact that illness lasted 10 days or more. Two children in this group required second administration of IVIG and another two patients received glucocorticosteroids as additional treatment. In our study, almost half of the patients still required ASA treatment at 6-week follow-up due to persistent changes in the cardiovascular system. 041b061a72